Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264295 | 0.91 | MGAT2 (0.42) | MGAT2DGAT2NR1H2ESR2MKNK1 | |
| SCHEMBL8264338 | 0.90 | CHRM5 (0.46) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8263936 | 0.87 | USP30 (0.43) | MGAT2DGAT2MKNK1MMP13ABL1 | |
| SCHEMBL8265951 | 0.86 | MKNK1 (0.42) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8253723 | 0.84 | ESR2 (0.52) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8261717 | 0.84 | CHRM2 (0.51) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL7052243 | 0.83 | SLC6A3 (0.58) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8263641 | 0.83 | CHRM2 (0.45) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10181943 | 0.83 | CHRM2 (0.45) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL6418231 | 0.82 | CHRM5 (0.59) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | CHRM5 645/4885CHRM1 1710/4885CHRM2 2568/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | CHRM5 1754/4885CHRM1 1634/4885CHRM2 2831/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | CHRM5 2292/4885CHRM1 1948/4885CHRM2 3139/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | CHRM5 1595/4885CHRM1 2057/4885CHRM2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.